| [1] |
杜涛, 袁文茜, 曹伯旭, 等. 慢性神经病理性疼痛[J]. 中国疼痛医学杂志, 2021, 27(7): 481-485.
|
| [2] |
Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD11: chronic neuropathic pain[J]. Pain, 2019, 160(1): 53-59.
|
| [3] |
Yin D, Chen Y, Li Y, et al. Interleukin-1 receptor associated kinase 1 mediates the maintenance of neuropathic pain after chronic constriction injury in rats[J]. Neurochem Res, 2019, 44(5): 1214-1227.
|
| [4] |
朱谦, 樊碧发, 张达颖, 等. 周围神经病理性疼痛诊疗中国专家共识[J]. 中国疼痛医学杂志, 2020, 26(5): 321-328.
|
| [5] |
Weerink M, Struys M, Hannivoort LN, et al.Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine[J]．Clin Pharmacokinet, 2017, 56(8): 893-913.
|
| [6] |
Zhao Y, He J, Yu N, et al. Mechanisms of dexmedetomidine in neuropathic pain[J]. Front Neurosci, 2020, 14: 330.
|
| [7] |
Serednicki WT, Wrzosek A, Woron J, et al. Topical clonidine for neuropathic pain in adults[J]. Cochrane Database Syst Rev, 2022, 5(5): CD010967.
|
| [8] |
Xun S, Zheng R. Dexmedetomidine alleviates neuropathic pain by regulating JAK/STAT pathway in rats[J]. J Cell Biochem, 2020, 121(3): 2277-2283.
|
| [9] |
张应涛,张庆,田杰利,等.七氟烷联合右美托咪定对腹腔镜下子宫肌瘤切除术患者生命体征、血清炎性因子和疼痛介质P物质、前列腺素E2的影响[J].现代生物医学进展, 2022, 22(18): 3573-3576, 3600.
|
| [10] |
张晓晓,马岳,胡越成,等.右美托咪定对不同组织系统离子通道的作用[J].医学综述, 2020, 26(23): 4739-4744.
|
| [11] |
Han QQ, Li XY, Wang YX. Dexmedetomidine attenuates lipopolysaccharide-induced inflammation through macrophageal IL-10 expression following α7 nAchR activation[J]. Int Immunopharmacol, 2022, 109: 108920.
|
| [12] |
Xu S, Yi Y, Wang Y, et al. Dexmedetomidine alleviates neuropathic pain via the TRPC6-p38 MAPK pathway in the dorsal root ganglia of rats[J]. J Pain Res, 2022, 15: 2437-2448.
|
| [13] |
Ji RR, Nackley A, Huh Y, et al. Neuroinflammation and central sensitization in chronic and widespread pain[J]. Anesthesiology, 2018, 129(2): 343-366.
|
| [14] |
Shan W, Liao X, Tang Y, et al. Dexmedetomidine alleviates inflammation in neuropathic pain by suppressing NLRP3 via Nrf2 activation[J]. Exp Ther Med, 2021, 22(4): 1046.
|
| [15] |
Qiu Z, Lu P, Wang K, et al. Dexmedetomidine inhibits neuroinflammation by altering microglial M1/M2 polarization through MAPK/ERK pathway[J]. Neurochem Res, 2020, 45(2): 345-353.
|
| [16] |
Jian SL, Chen WW, Su YC, et al. Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis[J]. Cell Death Dis, 2017, 8(5): e2779.
|
| [17] |
Magar S, Nayak D, Mahajan UB, et al. Retraction Note: Ultra-diluted toxicodendron pubescens attenuates pro-inflammatory cytokines and ROS-mediated neuropathic pain in rats[J]. Sci Rep, 2019, 9(1): 8641.
|
| [18] |
Liu P, Chen T, Tan F, et al. Dexmedetomidine alleviated neuropathic pain in dorsal root ganglion neurons by inhibition of anaerobic glycolysis activity and enhancement of ROS tolerance[J]. Biosci Rep, 2020, 40(5): BSR20191994.
|
| [19] |
Arruri V, Komirishetty P, Areti A, et al. Nrf2 and NF-kappa B modulation by Plumbagin attenuates functional, behavioural and biochemical deficits in rat model of neuropathic pain[J]. Pharmacol Rep, 2017, 69(4): 625-632.
|
| [20] |
Zhao L, Zhai M, Yang X, et al. Dexmedetomidine attenuates neuronal injury after spinal cord ischaemia-reperfusion injury by targeting the CNPY2-endoplasmic reticulum stress signalling[J]. J Cell Mol Med, 2019, 23(12): 8173-8183.
|
| [21] |
Lu Y, Lin B, Zhong J. The therapeutic effect of dexmedetomidine on rat diabetic neuropathy pain and the mechanism[J]. Biol Pharm Bull, 2017, 40(9): 1432-1438.
|
| [22] |
Rodríguez-González R, Sobrino T, Veiga S, et al. Neuroprotective effects of dexmedetomidine conditioning strategies: evidences from an in vitro model of cerebral ischemia[J]. Life Sci, 2016, 144: 162-169.
|
| [23] |
Feng P, Zhang A, Su M, et al. Dexmedetomidine inhibits apoptosis of astrocytes induced by oxygen-glucose deprivation via targeting JAK/STAT3 signal pathway[J]. Brain Res, 2021, 1750: 147141.
|
| [24] |
Wang K, Wu M, Xu J, et al. Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: systematic review and meta-analysis[J]. Br J Anaesth, 2019, 123(6): 777-794.
|
| [25] |
Cai QH, Tang Y, Fan SH, et al. In vivo effects of dexmedetomidine on immune function and tumor growth in rats with ovarian cancer through inhibiting the p38 MAPK/NF-κB signaling pathway[J]. Biomed Pharmacother, 2017, 95: 1830-1837.
|
| [26] |
Brinkman JE, Sharma S. Physiology, sleep. StatPearls[Internet]. Treasure Island, FL: StatPearls Publishing, 2018.p. 18e28.
|
| [27] |
Zhao E, Bai L, Li S, et al. Dexmedetomidine alleviates CCI-induced neuropathic pain via inhibiting HMGB1-mediated astrocyte activation and the TLR4/NF-κB signaling pathway in rats[J]. Neurotox Res, 2020, 38(3): 723-732.
|
| [28] |
Zhang W, Yu T, Cui X, et al. Analgesic effect of dexmedetomidine in rats after chronic constriction injury by mediating microRNA-101 expression and the E2F2-TLR4-NF-κB axis[J]. Exp Physiol, 2020, 105(9): 1588-1597.
|
| [29] |
Obata H. Analgesic mechanisms of antidepressants for neuropathic pain[J]. Int J Mol Sci, 2017, 18(11): 2483.
|